Genome editing provides an exciting avenue for the treatment of severe forms of human disease such as DMD. In fact, recent work illustrates the potential power of in vivo CRISPR (clustered regularly interspaced short palindromic repeats)-mediated genome editing for DMD treatment. [6] [7] [8] [9] [10] [11] [12] However, to date the impact of this approach on DMD cardiac muscle function has not been evaluated. We previously showed that SpCas9 (clustered regularly interspaced
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uchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy affecting ≈1 in 3500 live male births. 1 DMD is caused by mutations in the dystrophin gene (DMD) that results in the absence of dystrophin, 2 a critical component of the dystrophin-glycoprotein complex that integrates cytoskeleton with the extracellular matrix. As a consequence, progressive muscle degeneration occurs resulting in the development of cardiac dysfunction and respiratory muscle weakness that ultimately leads to premature death. 3 Notably, cardiomyopathy develops in >90% of DMD patients and represents the leading cause of death in DMD patients. 4, 5 Current treatments for DMD-associated cardiomyopathy include glucocorticoids in conjunction with either angiotensin-converting enzyme inhibitors or β-blockers; however, these treatments focus on preserving residual muscle strength and extending lifespan, not the prevention of disease pathogenesis. September 29, 2017 short palindromic repeat-associated 9 from Streptococcus pyogenes)/guide RNA (gRNA) can restore dystrophin reading frame in skeletal muscle of mdx mice. SpCas9/gRNA constructs were packaged into an adenovirus and delivered locally and systemically demonstrating the efficiency of the SpCas9/gRNA in restoring the expression of dystrophin protein in mdx heart as detected by immunofluorescence and immunoblotting. However, adenovirus is highly antigenic, has limited translational ability, and was only able to transduce a limited layer of the heart mainly pericardial which limits its therapeutic potential. Therefore, we attempted to package our SaCas9 (Cas9 from Staphylococcus aureus)/gRNA constructs into an adeno-associated virus (AAV) serotype rh.74, and we delivered it to mdx/Utr +/− mice systemically via a retro-orbital approach. Our results not only showed restoration of the dystrophin protein expression but also demonstrated the restoration of the cardiac myofiber architecture, and reduction of the fibrotic area within the heart was also observed. Furthermore, functional improvement of the contractility of papillary muscles was evident in the AAVtreated mice versus the untreated control mdx/Utr +/− mice.
Methods
Detailed methods can be found in the Online Data Supplement.
Results

Systemic Adenovirus-Cas9/gRNAs Delivery in mdx Mice Restores Dystrophin Expression in the Pericardial Muscles
The mdx mouse has been used extensively as a mouse model for DMD. It carries a point mutation at exon 23 resulting in the disruption of dystrophin expression in both skeletal and cardiac muscles. 13 We previously demonstrated that in-frame deletion of the genomic DNA covering exons 21, 22, and 23 restored functional dystrophin expression in skeletal muscles of mdx mice using intramuscular adenovirus Cas9/gRNAs delivery. 6 Here, we attempted to deliver the adenovirus Cas9/ gRNAs into mdx neonates (postnatal day 1-3) and test the hypothesis that CRISPR gene editing could restore cardiac dystrophin expression. The adenovirus carries a green fluorescent protein cassette to illustrate transduction into the heart in mdx mice. Cardiac dystrophin expression was restored in the adenovirus Cas9/gRNAs-treated mdx mice, as evidenced by immunofluorescence, polymerase chain reaction (PCR), and immunoblotting (Online Figures I and II) . These studies demonstrate that CRISPR-mediated genome editing allows excision of the mutant exon in dystrophin-deficient mice and restoration of dystrophin expression in the heart muscle. However, consistent with previous report, 14 adenovirus has limited transduction efficiency to the heart and it only targets peripheral myocardium as shown in Online Figure  III . Therefore, we subsequently tested systemic delivery of CRISPR/Cas9 using AAV in dystrophic mice.
Both SpCas9 and SaCas9 Are Highly Efficient in Editing the Dystrophin Gene
In the adenovirus CRISPR system, we used SpCas9, whose size is very close to the packaging limit of the AAV. Therefore, we sought to use a smaller version of SaCas9 for efficiently packaging into the AAV vector. For comparison, we designed the gRNAs for SaCas9 to target the same regions as for SpCas9 ( Figure 1A ). When electroporated into C2C12 cells, both SpCas9/gRNAs and SaCas9/gRNAs induced efficient gene editing as evidenced by PCR analysis of the genomic DNA. A 500-bp PCR product as predicted could be amplified from both Cas9-treated samples, but not in the control cells ( Figure 1B Duchenne muscular dystrophy is the most common form of muscular dystrophy that affects 1:3500 live male births. As the disease progresses, life-threatening cardiac complications can occur and most patients die in early adulthood. There is no current treatment for the disease and no cure to stop its progression to heart damage. Here, we showed that genome editing efficiently corrected the genetic defect in a mouse model of Duchenne muscular dystrophy and restored dystrophin protein expression in the heart muscles to nearly 40%. There was also a noted improvement in the architecture of heart muscle fibers, pathological changes, and contractile strength. Our study demonstrates that genome editing can restore dystrophin expression and heart function in dystrophic mice after a single treatment. This study holds great promise for the treatment of Duchenne muscular dystrophy patients.
( Figure 1C ). Although slightly less efficient than SpCas9/ gRNAs, SaCas9/gRNAs transfection also resulted in over 50% reduction of the wild-type transcript ( Figure 1C ). Moreover, DNA sequencing confirmed that the 500-bp transcript in Figure 1B amplified from C2C12 cells treated with gRNA/ SaCas9 was formed because of successful deletion of exons 21 to 23 ( Figure 1D ). We then package the SaCas9/gRNAs into AAVrh74, a serotype shown to be nonpathogenic and mediate effective transgene expression in striated muscles.
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Systemic Delivery of AAV-SaCas9/gRNAs Restores Dystrophin Protein Expression in Cardiac Muscle
For the AAV study, we chose the mdx/Utr +/− mice because these animals exhibit a more severe phenotype and mimic human DMD patients better than the mdx mice because of the reduced compensation from the dystrophin homologue utrophin. 19 In particular, cardiomyopathy develops earlier in these mice and is much more severe, making the mdx/Utr +/− mice an excellent model to study potential cardiac therapeutics. 20 Systemic delivery of AAV-SaCas9/gRNAs (low dose, 3×10 11 or high dose, 1×10 12 vg per mouse) was performed in (day 3) mdx/Utr +/− neonates. At 10 weeks after treatment, the heart muscles of the animals were analyzed for dystrophin expression by immunofluorescence staining. The low-dose treatment group showed scattered dystrophin-positive fibers (Figure 2A ), whereas the high-dose treatment restored dystrophin expression widely in many cardiomyocytes across the entire heart section of mdx/Utr +/− mice ( Figure 2B ). At a higher magnification, dystrophin was found to be correctly localized at the sarcolemma of the cardiomyocytes ( Figure 2C ). For the high-dose treatment group, we found that ≈40% (39.0±0.4%, n=4) of cardiomyocytes were dystrophin positive ( Figure 3A) .
Real-time PCR analysis of the hearts showed that the edited smaller dystrophin transcript was expressed in all AAVtreated mdx/Utr +/− samples ( Figure 3B ). Immunoblotting also confirmed the expression of dystrophin protein in the AAV-SaCas9/gRNAs-treated mdx/Utr +/− hearts ( Figure 3C ). Densitometry analysis of the dystrophin bands showed that it was restored to 23.3±5.1% of the wild-type level ( Figure 3D) .
To assess the nonhomologous end joining events occurred at the gRNA target sites, we performed targeted deep sequencing of PCR amplicons from both gRNA annealing sites (left, amplicon A; right, amplicon B; Online Figure IV and Sequences). In addition, we performed targeted deep sequencing of the amplicon spanning across the junction connecting the left and right sides. This amplicon represents the deletion of ≈23 kb from chromosome X because of CRISPR/ Cas9-guided nonhomologous end joining in vivo (amplicon C). We used both Illumina (Online Figure IV) and Ion Torrent platforms (data not shown). Very few insertions, deletions, or base substitutions were detected in amplicon A, and only slightly more were detected in amplicon B (Online Figure  IVA and IVB) . By contrast, most sequences from amplicon C showed that the end joining between targets A and B was almost always perfect, deleting ≈23 kb of intervening genomic sequences, just as we had designed (Online Figure IVC and  IVD) . We found that 76% of all targeted sequences from amplicon C showed precise joining because of CRISPR/Cas9, and 86% of these sequences revealed no or only very short (<5 nt) insertions or deletions at the desired recombinant junction site (Online Figure IVD) . In addition, very low numbers of individual mutations at one target site or the other were detected alone. This suggested that the gRNAs at A and at B did not typically operate alone, but instead coordinated together in deleting the intervening genomic sequences. Very similar results were obtained using both the Illumina MiSeq and Ion Torrent platforms. These results confirmed that our CRISPR/Cas9 recombination strategy was very highly effective in deleting the ≈23 kb of intervening genomic sequences.
Furthermore, to test if CRISPR-mediated genome editing could restore dystrophin expression in the adult heart of dystrophic mice, we administered AAV-SaCas9/gRNAs (1×10 12 vg per mouse) into mdx/Utr +/− mice at the age of 16 weeks by tail vein injection. As shown in Online Figure V , measurable restoration of dystrophin protein was also detected using immunofluorescence 7 days after the treatment.
Overall, this is highly encouraging that a single systemic treatment with AAV-SaCas9/gRNAs restored the expression in nearly half of the cardiomyocytes across the entire heart of dystrophin-deficient mice. Therefore, we further examined whether the observed levels of dystrophin restoration results in pathological and functional improvements in the cardiac muscles of mdx/Utr +/− mice.
Dystrophin Restoration in AAV-CRISPR/SaCas9-Treated mdx/Utr +/− Mice Results in Decreased Cardiac Fibrosis and Improved Contractility of Papillary Muscles
Histological analysis was performed to determine whether the restored cardiac dystrophin expression also resulted in reduced cardiac pathology. Haemotoxylin and Eosin staining illustrated cardiac muscle architecture, and Sirius Red/Fast Green staining illustrated the amount of fibrosis present in the heart. Reduced fibrosis was visually noticed in the AAVSaCas9/gRNAs-injected mice ( Figure 4A) . By measuring the fibrotic area, we found that AAV-CRISPR/Cas9-treated mice had significantly reduced fibrotic area over the total heart cross section when compared with untreated controls (Figure 4B ).
To determine whether the gene editing treatment also improves cardiac function, we studied the contractility of the isolated papillary muscle at 10 weeks. 21 Three main mechanisms of cardiac contractile regulation were assessed as previously described, 22, 23 including length-dependent activation, frequency-dependent activation, and β-adrenergic stimulation. The length-dependent activation was evaluated by recording the contractile parameters at 85%, 90%, 95%, and 100% of optimal muscle length. A statistically significant increase in (n≥3 per group) . B, Quantitative analysis of fibrotic area from Sirius Red/Fast Green stained mdx/Utr +/− heart cryosections with or without AAV-SaCas9/gRNAs (n≥3 per group). C, Length-dependent activation of heart contractility evaluated by recording the contractile parameters at 85%, 90%, 95%, and 100% of optimal length (n=5 for untreated mdx/Utr +/− and 6 for AAV-mdx/Utr force at 100% optimal muscle length was observed in the mdx/ Utr +/− AAV-treated hearts compared with the untreated hearts ( Figure 4C ). The force-frequency response was measured at optimal length by adjusting the stimulation frequency from 4 to 6, 8, 10, 12, and 14 Hz, with 2-to 3-minute stabilization time between each frequency. Results also showed a statistically significant increase in force at 8, 10, and 14 Hz in the AAV-treated hearts versus mdx/Utr +/− controls ( Figure 4D ). Finally, after allowing the muscle to stabilize for 10 minutes at 4 Hz, the β-adrenergic responsiveness was assessed by measuring the contractile parameters with the addition of isoproterenol at semilog steps between 1 nmol/L and 1 μmol/L. Data demonstrated no significant difference in the β-adrenergic responsiveness in the AAV-treated group versus the untreated controls to the increase in isoproterenol concentration ( Figure 4E ).
Discussion
DMD is one of the most common genetic diseases, and DMD patients lose their life prematurely because of respiratory or cardiac complications. 5, 24 Therefore, an effective therapy for DMD needs to address the complications in both the skeletal muscle and heart. Previous studies from others and us showed that CRISPR-based genome editing effectively restored dystrophin expression in the skeletal muscle of a postnatal mouse model of DMD. [6] [7] [8] [9] [10] [11] [12] In the present study, we presented data to demonstrate that AAV-mediated systemic delivery of CRISPR reagents leads to cardiac dystrophin expression and functional improvement, further highlighting the therapeutic promise of genome editing therapy for DMD.
Several therapeutic strategies have been explored to treat the primary cause of DMD by restoring dystrophin expression, such as mini-dystrophin cDNA, exon skipping, and genome editing. Both mini-dystrophin cDNA and exon skipping have shown therapeutic potential in limiting DMD progression, whereas both strategies have their limitations. The mini-dystrophins are potentially less functional and more immunogenic because of the large deletions and altered protein structure, 25 whereas exon skipping showed only transient restoration of dystrophin, [26] [27] [28] requiring frequently repeated treatments. A more revolutionary approach was recently brought to the DMD therapeutic arena, which takes advantage of the CRISPR/Cas9 genome editing technology. CRISPR/Cas9 was originally discovered in bacteria as a defense mechanism whereby the Cas9 enzyme cleaves foreign nucleic acids. 29 The CRISPR/Cas9 system has been modified for genome editing as it can precisely cleave a specific target sequence based on the gRNA supplied. 29, 30 Previous work performed by Long et al 8 demonstrated that injecting Cas9, gRNA, and a single-stranded oligodeoxynucleotide donor template into the one-cell embryo of mdx mice resulted in correction of the dystrophin mutation in the offspring through homologous recombination. However, this technique has limited translational abilities. A subsequent study by Ousterout et al 10 in 2015 used CRISPR/ Cas9 and gRNAs to correct specific mutations in myoblasts from DMD patients. More recently, our laboratory demonstrated for the first time that CRISPR/Cas9 could restore the expression of dystrophin protein and dystrophin-glycoprotein complex components in postnatal mdx mice. 6 Functional improvements in the edited muscles were observed, as skeletal muscle was protected from damage during downhill treadmill running. Soon after, 3 other laboratories published their studies that used AAV to deliver the CRISPR/Cas9 and gRNAs either systemically or intramuscularly into mdx mice. 7, 9, 11 Earlier this year, a study by Bengtsson et al 12 demonstrated a restoration of dystrophin ≤70% in the skeletal muscles with increased force generation after local muscular delivery. Moreover, systemic administration of their AAV vectors resulted in dystrophin expression in both skeletal and cardiac muscles. All these studies demonstrated some levels of dystrophin restoration in skeletal and cardiac muscles. However, functional assessment of the edited hearts has not been explored. Therefore, the present study is the first to demonstrate that a single AAV injection through a retro-orbital approach could restore dystrophin expression in nearly 40% cardiac muscle fibers across the entire heart and demonstrate a significant functional improvement in cardiac contractility in the mdx/Utr +/− mouse model. The major advantage of the CRISPR-based genome editing therapy for DMD is that such a treatment would be permanent. However, there are also several concerns for moving this strategy forward into clinical trials. First, the most often used CRISPR/Cas9 systems (SpCas9 or SaCas9) are well known for their off-target activities. The off-target activities resulting from the nontargeted cleavage in vivo could be potentially dangerous, in particular with the long-lasting expression mediated by AAV delivery. In this regards, the recently reported high-fidelity Cas9 engineering is encouraging. 31, 32 Second, Cas9 protein may activate cellular immune response as a recent study reported that expression of SpCas9 in adult tibialis anterior muscle evoked host immune response regardless of delivery method. 33 Interestingly, this same study 33 did not observe significant cytolytic activities resulting from the AAV-CRISPR/Cas9 delivery even though it activates the host immunity. Nevertheless, there is little concern of immune response in the present study as we injected the AAV into pups at the age of days 1 to 3 when the immune system has not been fully developed. Finally, the delivery technology is still the bottleneck and awaiting major breakthroughs as for all other gene therapy approaches. Currently, AAV is one of the most widely used delivery vehicles for gene therapy. However, the delivery efficiency, packaging capacity, tissue specificity, immuneactivating potential, temporal control, and dosage control are all of concern and needed to be taken into consideration for engineering more efficient delivery tools in the future.
In summary, our data showed the clear evidence of restoration of cardiac muscle function in genetically edited dystrophin-deficient hearts of postnatal mice. In addition, our targeted deep sequencing results confirmed that our AAV-CRISPR/Cas9 strategy was very efficient in deleting the ≈23 kb of intervening genomic sequences. Although future studies are required to deal with many associated issues such as offtarget activities, immunologic responses, delivery efficiency, delivery to adult mice, temporal control, and tissue specificity, our current study together with previous studies suggests that in vivo gene editing holds a great promise as a permanent therapy for DMD.
